A Phase 2 interventional study of Placebo and LY3041658 in Hidradenitis Suppurativa, sponsored by Eli Lilly and Company. Completed at 20 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 61st largest by enrollment of the 139 interventional ones that give a count, is one of 16 that started in 2020, is one of 61 in phase 2, and was the 65th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 2 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received 600 mg LY3041658 administered intravenously (IV) once every 2 weeks (Q2W).
Drug: LY3041658
Placebo administered IV. Participants will switch to 600 mg LY3041658 administered IV after week 16.
Drug: Placebo · Drug: LY3041658
Administered IV
Administered IV
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16
The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.
Time frame: Week 16
Mean Change From Baseline to Week 16 in Total Number of Abscesses and Inflammatory Nodules (AN) Count
Mean Change from baseline in total AN count at Week 16 was reported. Abscess and inflammatory nodule were counted for the Hidradenitis Suppurativa (HS) affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
Time frame: Baseline, Week 16
Mean Change From Baseline to Week 16 in Skin Pain on the HS Numeric Rating Scale (NRS)
The Skin Pain - HS Numeric Rating Scale (NRS) is a patient-administered, single-question, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no skin pain" and 10 representing "skin pain as bad as you can imagine." The recall period is 7 days.
Time frame: Baseline, Week 16
| Milestone | Placebo/600 mg LY3041658 | 600 mg LY3041658 / 600 mg LY3041658 |
|---|---|---|
| Started | 24 | 48 |
| Received at least one dose of study drug | 22 | 45 |
| Completed | 14 | 38 |
| Not completed | 10 | 10 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Other, relocation | 0 | 1 |
| Withdrew: Other, protocol deviation | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Randomized but never treated | 2 | 3 |
| Milestone | Placebo/600 mg LY3041658 | 600 mg LY3041658 / 600 mg LY3041658 |
|---|---|---|
| Started | 14 | 38 |
| Received at least one dose of study drug | 13 | 36 |
| Completed | 10 | 29 |
| Not completed | 4 | 9 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 8 |
| Milestone | Placebo/600 mg LY3041658 | 600 mg LY3041658 / 600 mg LY3041658 |
|---|---|---|
| Started | 10 | 29 |
| Completed | 8 | 24 |
| Not completed | 2 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 |
The HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (sum of abscesses and inflammatory nodules \[AN count\]) with no increase in abscess count (A count) and no increase in draining fistulae count (DF count) relative to baseline. Non-responder imputation (NRI): Participants with missing data were considered non-responders.
| percentage of participants | Placebo | 600 mg LY3041658 |
|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 | 31.8 (12.4 to 51.3) | 48.9 (34.3 to 63.5) |
Mean Change from baseline in total AN count at Week 16 was reported. Abscess and inflammatory nodule were counted for the Hidradenitis Suppurativa (HS) affected anatomical regions. The AN count is the sum of number of abscess and inflammatory nodules across anatomical regions.
| count of abscess and inflammatory nodule | Placebo | 600 mg LY3041658 |
|---|---|---|
| Mean Change From Baseline to Week 16 in Total Number of Abscesses and Inflammatory Nodules (AN) Count | -1.85 ± 1.636 | -6.52 ± 1.133 |
The Skin Pain - HS Numeric Rating Scale (NRS) is a patient-administered, single-question, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no skin pain" and 10 representing "skin pain as bad as you can imagine." The recall period is 7 days.
| units on a scale | Placebo | 600 mg LY3041658 |
|---|---|---|
| Mean Change From Baseline to Week 16 in Skin Pain on the HS Numeric Rating Scale (NRS) | -1.83 ± 0.614 | -1.78 ± 0.418 |
Collected over Baseline Up to Follow-up Period (46 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 600 mg LY3041658 _Double-Blind Treatment Period | 0/45 (0%) | 0/45 (0%) | 10/45 (22.2%) |
| Placebo_Double-Blind Treatment Period | 0/22 (0%) | 2/22 (9.1%) | 2/22 (9.1%) |
| 600 mg LY3041658_Open-Label Extension | 0/49 (0%) | 1/49 (2%) | 13/49 (26.5%) |
| Follow-Up Period | 0/39 (0%) | 0/39 (0%) | 2/39 (5.1%) |
| Event | 600 mg LY3041658 _Double-Blind Treatment Period | Placebo_Double-Blind Treatment Period | 600 mg LY3041658_Open-Label Extension | Follow-Up Period |
|---|---|---|---|---|
| Post procedural infectionInfections and infestations | 0/45 | 1/22 | 0/49 | 0/39 |
| Aortic stenosisVascular disorders | 0/45 | 1/22 | 0/49 | 0/39 |
| Atrial fibrillationCardiac disorders | 0/45 | 0/22 | 1/49 | 0/39 |
| PneumoniaInfections and infestations | 0/45 | 0/22 | 1/49 | 0/39 |
| Event | 600 mg LY3041658 _Double-Blind Treatment Period | Placebo_Double-Blind Treatment Period | 600 mg LY3041658_Open-Label Extension | Follow-Up Period |
|---|---|---|---|---|
| Covid-19Infections and infestations | 2/45 | 1/22 | 5/49 | 1/39 |
| BalanoposthitisReproductive system and breast disorders | 1/10 | 0/10 | 0/12 | 0/11 |
| Scrotal operationSurgical and medical procedures | 0/10 | 1/10 | 0/12 | 0/11 |
| NasopharyngitisInfections and infestations | 0/45 | 0/22 | 4/49 | 0/39 |
| ConstipationGastrointestinal disorders | 3/45 | 0/22 | 0/49 | 0/39 |
| NauseaGastrointestinal disorders | 3/45 | 0/22 | 0/49 | 1/39 |
| FatigueGeneral disorders | 3/45 | 0/22 | 0/49 | 0/39 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/45 | 0/22 | 2/49 | 0/39 |
| Upper respiratory tract infectionInfections and infestations | 0/45 | 0/22 | 3/49 | 0/39 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo/600 mg LY3041658 | 600 mg LY3041658 / 600 mg LY3041658 | Total |
|---|---|---|---|
| Mean | 36.10 ± 12.68 | 37.10 ± 12.38 | 36.80 ± 12.39 |
| Sex: Female, Male(Participants) | Placebo/600 mg LY3041658 | 600 mg LY3041658 / 600 mg LY3041658 | Total |
|---|---|---|---|
| Female | 12 | 35 | 47 |
| Male | 10 | 10 | 20 |
| Ethnicity (NIH/OMB)(Participants) | Placebo/600 mg LY3041658 | 600 mg LY3041658 / 600 mg LY3041658 | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 7 | 13 |
| Not Hispanic or Latino | 15 | 35 | 50 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Race (NIH/OMB)(Participants) | Placebo/600 mg LY3041658 | 600 mg LY3041658 / 600 mg LY3041658 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 12 | 17 |
| White | 16 | 30 | 46 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo/600 mg LY3041658 | 600 mg LY3041658 / 600 mg LY3041658 | Total |
|---|---|---|---|
| Australia | 2 | 5 | 7 |
| United States | 20 | 40 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Aug 2020 to primary completion in Mar 2022, 18 months.
Results were first posted in Apr 2023, 1 year 1 month after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 18 months is above that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrekibart